The use of emerging nanotechnologies, such as plasmonic nanoparticles in diagnostic applications, potentially offers opportunities to revolutionize disease management and patient healthcare. Despite worldwide research effort in this area, there is still a dearth of nanodiagnostics which have been successfully translated for real-world patient usage due to the predominant sole focus on assay analytical performance and lack of detailed investigations into clinical performance in human samples. In a bid to address this pressing need, we herein describe a comprehensive clinical verification of a prospective label-free surface-enhanced Raman scattering (SERS) nanodiagnostic assay for prostate cancer (PCa) risk stratification. This contribution depicts a roadmap of 1) designing a SERS assay for robust and accurate detection of clinically-validated PCa RNA targets; 2) employing a relevant and proven PCa clinical biomarker model to test our nanodiagnostic assay; 3) investigating the clinical performance on independent training (n = 80) and validation (n = 40) cohorts of PCa human patient samples. By relating the detection outcomes to goldstandard patient biopsy findings, we established a PCa risk scoring system which exhibited a clinical sensitivity and specificity of 0.87 and 0.90, respectively [area-under-curve of 0.84 (95% confidence interval: 0.81-0.87) for differentiating high-and low-risk PCa] in the validation cohort. We envision that our SERS nanodiagnostic design and clinical verification approach may aid in the individualized prediction of PCa presence and risk stratification; and may overall serve as an archetypical strategy to encourage comprehensive clinical evaluation of nanodiagnostic innovations.
The use of nanoparticles such as plasmonic surface-enhanced Raman scattering (SERS) nanoparticles or fluorescent quantum dots, has been shown to be promising for disease diagnostics applications. [1] [2] [3] [4] Yet, to date, there is still a dearth of nanoparticle-based diagnostics which have been translated for use in the clinic. This is partly attributed to the limited clinical technology verification studies for evaluating the clinical sensitivity and specificity (i.e. extent of false positives/negatives outcomes) of a diagnostic assay. 5, 6 Typically, these clinical diagnostic metrics are obtained by testing on statistically-designed cohorts of annotated patient samples as a demonstration of clinical suitability. Progress on this front has been made by Chan and colleagues who recently reported a full clinical validation of QD barcode technology for diagnosing patients infected with Hepatitis B Virus (HBV). 7 Ideally, this clinical validation concept could also be extended to the powerful SERS technique which has seen widespread use in biosensing research. SERS has been demonstrated as a facile tool for direct nucleic acid (NA) biomarker analysis without the need for time-consuming, tedious, and costly extrinsic labeling. [8] [9] [10] [11] [12] SERS involves the direct adsorption of NA sequences onto metallic nanostructured surfaces to generate selective sequence-dependent Raman spectral signatures. Due to recent advances in improving NA-SERS plasmonic substrate interactions, there have been vast improvements in SERS signal strength and reproducibility for NA biosensing. 9, 13, 14 This has led to a real possibility for translation of SERS technology for clinical use, as exemplified by an initial demonstration of SERS detection of RNA biomarkers in patient urine samples. 15 However, it is still imperative to progress beyond these promising proof-of-concept analytical studies, and further investigate the clinical performance of SERS as a nanodiagnostic tool for patient use.
To achieve this, SERS is to be ideally applied to a clinically-validated panel of disease biomarkers: a procedure which is rarely undertaken in the majority of nanodiagnostic publications. This has thus motivated us to undertake a comprehensive clinical verification of SERS by interrogating its clinical metrics with a well-suited cancer risk stratification scoring model.
Prostate cancer (PCa) is the most commonly diagnosed male cancer, with early detection currently based on serum prostate specific antigen (PSA) to facilitate early treatment and improved survival. In spite of its widespread use, biological variation of the PSA biomarker in individuals has resulted in unreliable diagnostic accuracy, and associated side effects of unnecessary biopsies. [16] [17] [18] [19] In contrast, the Mi-Prostate Score (MiPS) is a PCa risk score test which was developed recently to improve the well-known deficiencies of PSA testing in early PCa detection. MiPS combines the urinary quantification of PCa-specific RNA targets, TMPRSS2:ERG (T2:ERG) and PCA3, to predict a patient's possibility of having PCa before biopsy diagnosis. Thus far, the combined detection of T2:ERG and PCA3 in the MiPS test has been clinically validated on around 2000 patients, and shown to provide a significantly better PCa risk assessment than serum PSA alone. 20-24 Therefore, MiPS is an ideal NA biomarker-driven clinical model to implement SERS detection of T2:ERG and PCA3 for early PCa risk prediction. Furthermore, MiPS is currently performed through lengthy and multi-step laboratory testing and has not been previously adopted by any sort of nanodiagnostic technique. Thus, we rationalized that MiPS clinical performance could benefit from the integration of a NA detection nanotechnology, such as ultrasensitive SERS, in terms of enhanced detection sensitivity and speed.
In this work, we described the use of a SERS nanodiagnostic technology for early PCa risk stratification by detecting T2:ERG and PCA3 PCa biomarkers in patient samples;
and employed an appropriate MiPS clinical model to evaluate performance in a clinicallydriven manner. We first prepared cationic silver nanoparticles (AgNPs) to generate distinct and reproducible SERS signals from pre-amplified T2:ERG and PCA3. A comprehensive clinical assay verification was then performed on initial training (n = 80), and subsequent validation (n = 40) cohorts of well-annotated patient samples. By following the algorithm of the clinically-validated MiPS, the generated biomarker SERS intensities were subsequently used to develop a PCa risk score for head-to-head comparisons with gold-standard tissue biopsy outcomes. Using this strategy of evaluating SERS nanotechnology from a clinical perspective, we successfully i) tailored our SERS_MiPS nanodiagnostic assay based on a proven clinically-useful PCa risk scoring model; ii) showcased enhanced detection speed of MiPS through SERS integration; iii) demonstrated the translational feasibility of SERS for patient usage via clinical metrics.
RESULTS AND DISCUSSION

Scheme
The working scheme and clinical verification workflow of our PCa nanodiagnostic assay, which coupled SERS with clinically-validated MiPS biomarkers (termed as "SERS_MiPS"), is illustrated in Figure 1 . Briefly, total RNA is extracted from patient urine samples, followed by parallel isothermal reverse transcription-recombinase polymerase amplification (RT-RPA) of three RNA targets (T2:ERG, PCA3, KLK2) (Figure 1a -i). This amplification step is employed to stabilize the native RNA targets in homogeneous double-stranded DNA (dsDNA) form, and to enhance resultant SERS signals. 15 The purified dsDNA amplicons are 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 magnetically-purified, and then directly mixed with cationic AgNPs colloidal suspensions for SERS measurements (Figure 1a 
SERS Substrate Characterization and Optimization
SERS is a surface spectroscopic technique for direct detection of adsorbed NA targets on a SERS substrate (typically metallic NPs) surface. The resulting signal strength of the adsorbed NA targets is dependent on multiple variables; including NP size and NA length. 25, 26 To achieve maximum SERS signals, we sought to optimize the size of cationic AgNPs for ultrasensitive target detection in patient samples.
We synthesized cationic AgNPs of different sizes, and compared their SERS signal enhancement for T2:ERG amplicons. Through adjusting the amount of reducing agents (NaBH4); we synthesized 20 nm, 40 nm, and 60 nm AgNPs (Figure 2a -c). The particle size distributions (PSDs) were further characterized by differential centrifugal sedimentation which measured NP sizes based on particle weight. Consistent with TEM data, the major peak maxima of PSDs indicated AgNP sizes of 20 nm, 40 nm, and 60 nm ( Figure 2d ). The corresponding surface plasmon resonance bands (Figure 2e ) showed a red-shift with increasing AgNP size, 394 nm for 20 nm AgNPs, 400 nm for 40 nm AgNPs and 413 nm for 60 nm AgNPs). This set of characterization experiments authenticated the successful synthesis of AgNPs with well-controlled sizes.
As SERS enhancement is dependent on the SERS substrate size, we observed stronger SERS signals for adsorbed T2:ERG amplicons on 40 nm AgNPs than on 20 nm AgNPs. However, for adsorbed T2:ERG amplicons on 60 nm AgNPs, SERS signals diminished due to excess NP aggregation and precipitation out of solution ( Figure 2f ). Therefore, cationic AgNPs at 40 nm was selected as the optimal SERS substrate to generate maximum signals for RNA biomarker detection in patient samples.
Analytical Specificity
The specificity of our methodology in detecting T2:ERG, PCA3, and KLK2 was first evaluated by assessing the isothermal amplification end-products of each target. Following rigorous primer design and testing on PCa cell lines, we verified using gel electrophoresis that each target amplification process generated corresponding amplicons of an expected band size ( Figure S1 ). This showed that each biomarker target could be specifically amplified from a heterogeneous mixture of cellular NA extract.
To demonstrate that SERS can specifically differentiate T2:ERG, PCA3, and KLK2 amplicon signals based on their selective molecular information, the SERS signals of T2:ERG, PCA3, and KLK2 amplicons were subjected to chemometric analysis. We used principal component analysis (PCA) to reduce the dimensionality of a multidimensional data set while retaining characteristics of all spectra. As shown in Figure 2g , PCA successfully identified and clustered Raman signals of T2:ERG, PCA3, and KLK2 amplicons into three separate groups, thus displaying significant differences within their SERS signals (P < 0.005).
Analytical Sensitivity
The limit-of-quantification (LOQ) for individual T2:ERG, PCA3, and KLK2 targets in patient samples was determined using serial dilutions (0 to 100 000 copies) of each biomarker (Figure 3a-c). As 10 copies generated similar saturating signal levels to that of 100 copies, it was found that a LOQ of 100 synthetic RNA copies in a background of healthy patient urinary RNA extract was achieved for all biomarkers within a dynamic range of 100 to 10 000 copies (Figure 3d -f). With this LOQ, the combination of RT-RPA and SERS used in our methodology imparted an improvement in analytical speed as compared to the current MiPS test. The standard MiPS test is presently accomplished through the combination of an alternative isothermal amplification technique called transcription-mediated amplification (TMA), and a chemiluminescence readout. 24 Although the LOQ of both our methodology and the current TMA-based test are comparable (Table S2 ), 27 we demonstrate that our nanotechnology-based methodology has significantly streamlined the assay workflow ( Fig.   S2 ) and shortened the total assay time (90 min vs 3-4 hrs). This could be attributed to the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 superior speed and amplification efficiency of RT-RPA which , 28 as well as the simplistic and rapid detection of target sequences by SERS. Additionally, our methodology also showed good assay reproducibility with intra-and inter-assay variability of 9.5% and 11.0% respectively (n = 3).
Disease Risk Scoring in Training Cohort
After demonstrating the analytical performance of our SERS_MiPS methodology for T2:ERG, PCA3, and KLK2 detection, we proceeded to test its clinical performance on human samples. We firstly aimed to refine our SERS_MiPS risk scoring system for early PCa diagnosis and prognosis by establishing functional cut off SERS signal levels for accurate PCa risk prediction. For this purpose, we used a training cohort (n = 80) that consisted of urine samples from 60 PCa patients and 20 healthy controls. Within the 60 PCa patient samples, we further defined low-and high-risk PCa subgroups on the basis of the patients' biopsy outcomes. Using the standard pathological Gleason grading of the biopsy tissues, lowrisk PCa was defined as Gleason score (GS)<7 and high-risk PCa as GS≥7. As shown in Table 1 , 36 (60%) and 24 (40%) of the PCa patients were in the low-and high-risk PCa subgroups, respectively.
As depicted in the heat map diagram (Figure 4a ), we obtained varying raw SERS signal intensities for the detection of T2:ERG, PCA3, and KLK2 in the training cohort of patient urine samples. Using the spectral peak at 742 cm -1 (assigned to purines), we quantified the raw SERS intensities as representative of the expression levels of each biomarker. The expression levels of T2:ERG ( Figure 4b ) and PCA3 (Figure 4c ) were then normalized by the level of KLK2 (to control for varying number of prostate cells and therefore, amount of prostate RNA amongst the patient samples). We also performed qPCR of the three biomarkers from the same patient samples as a separate validation tool (Table S2) , and attained good concordance between the qPCR and SERS biomarker expression data via Passing and Bablok regression analysis ( Figure S3 ). 29 It is also worth noting that the SERS and qPCR measurements were performed by different operators to ensure unbiased validation.
In accordance with the well-established MiPS PCa risk scoring algorithm, 24 the normalized SERS signals were then utilized to calculate a "%SERS_MiPS" value to estimate the risk of disease in the patients (Figure 4d ). By relating the %SERS_MiPS to the patients' biopsy GS results (Table S3 ), we found that all the healthy controls exhibited low %SERS_MiPS, and higher %SERS_MiPS was correlated with higher probability of a 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 positive PCa biopsy. Patients in high-risk PCa subgroups were also found to have overall higher %SERS_MiPS as compared to healthy controls and low-risk PCa subgroup patients ( Figure 4e ). Based on the %SERS_MiPS segregation for different PCa risk groups ( Figure   4e ), we primarily established a cut off of 20 %SERS_MiPS, at which above an individual is scored PCa-positive and below which a patient is considered PCa-negative (Figure 4e ). We also further set a cut off of 80 %SERS_MiPS for differentiating low-and high-risk PCa groups (Figure 4e ).
To evaluate clinical performance in the training cohort, we further analyzed the data 
Clinical Metric Evaluation in Validation Cohort
For a more in-depth validation of our developed SERS_MiPS, we used an independent validation cohort (n = 40) to verify the clinical efficacy of %SERS_MiPS cut off values. In addition, to provide a more realistic clinical screening scenario, the assay operator is blinded to the cohort's disease status and biopsy results to remove possible screening bias. This allows for a blind independent comparison of SERS_MiPS results with the reference biopsy results among a series of patients suspected (but not known) to have PCa until biopsy confirmation. Based on the subsequent biopsy data, the validation cohort was made up of 30 PCa patients with 18 (60%) and 12 (40%) in the low-and high-risk groups respectively, in addition to 10 healthy controls. In a similar fashion as to the training cohort, raw SERS signal intensities for T2:ERG, PCA3, and KLK2 were measured (Figure 5a ) with qPCR validation (Table S3 ), normalized to corresponding T2:ERG ( Figure 5b ) and PCA3 (Figure 5c ) levels, and generated into %SERS_MiPS scores (Figure 5d ). Using the established %SERS_MiPS cut offs from the training cohort, we separated the patients into different risk groups ( Figure   5e ). Through comparisons with patients' biopsy outcomes (Table S4) , we achieved a clinical 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 sensitivity and specificity of 0.87 and 0.90 respectively, and the AUC for predicting high-risk PCa is 0.84 (95% CI: 0.81-0.87) (Figure 5f ).
Clinical Performance of SERS_MiPS
By fusing the nanotechnological advantages of SERS and the validated clinical benefit of MiPS to create SERS_MiPS, our study goal was to validate the potential of this 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 growing nature of most PCa tumors, it is conceivable that low %SERS_MiPS scoring may play an invaluable role for monitoring patients managed by active surveillance, whilst high %SERS_MiPS scoring could identify patients for definitive and urgent evaluation. There are several avenues for building upon the outcomes of this contribution. From a clinical standpoint, it is imperative that the clinical studies be progressively up-scaled to evaluate SERS_MiPS at a greater population level. This ensuing step will also call for multiinstitutional studies to further cross-validate the nanodiagnostic technology. From a technological perspective, the emergence of handheld Raman spectrometers could enable SERS_MiPS to be increasingly user-friendly and amenable for point-of-care use. In addition, to exploit the multiplexing capability of SERS, our current proposed system could be further streamlined with greater analytical speed and convenience. This may be achieved by utilizing a multiplex target amplification process as well as developing advanced methods to decipher multiplex SERS spectra, but taking care to maintain appropriate analytical and clinical assay performance.
CONCLUSIONS
We anticipate that our careful study design, in incorporating a viable clinical risk stratification model (MiPS) and using two independent cohorts (training and validation) for a clinical verification of a nanodiagnotic technology, could serve as an archetypical strategy to encourage more studies towards clinical translation of promising innovations from nanotechnology laboratories for more widespread use. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 59 60
MATERIALS AND METHODS
Materials
All reagents were purchased from Sigma Aldrich, unless otherwise stated. Synthetic oligonucleotide and primer sequences used in our experiments were obtained from Integrated DNA Technologies (Singapore), and sequences are shown in Table S1 .
Cationic SERS Substrate Synthesis and Characterization
Cationic AgNPs were prepared as previously reported with ice-cold solutions. Briefly, 20 µL of 0.5 M AgNO 3 was added to 10 mL of distilled water, followed by the addition of 7 µL of 100 mM spermine. The mixture was vigorously stirred for 1 min. Then, various amounts of 10 mM NaBH 4 were added into the mixture to synthesize AgNPs of different sizes.
TEM images were taken with a Hitachi HT7700 microscope (Hitachi, Japan) operated at 120 kV. The size distribution of AgNPs was measured by differential centrifugal Table 1 .
Total RNA in the urinary samples was extracted using the commercially-available ZR urine RNA isolation Kit TM (Zymo Research, USA). Briefly, urinary cells were enriched by passing 30 mL of urine, followed by 700 µL of supplied urine RNA buffer through the supplied ZRC GF TM Filter. Collected urinary cells were then lyzed, washed and eluted in 10 µL of RNase-free water according to manufacturer's instructions. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 59 60
Isothermal Amplification of MiPS Biomarkers
The TwistAmp Basic RT kit (Twist-DX, UK) was used with slight modifications to manufacturer's instructions to specifically amplify each target RNA biomarker. Briefly, 1 µl of urinary extracted total RNA and 250 nM of target-specific (T2:ERG, PCA3, or KLK2) primers ( Table 1) were added to the supplied reagents to make a 12.5 µl of reaction volume.
Each reaction was then incubated at 41°C for 15 min. Afterwhich, amplicons were purified using the Agencourt AMPure XP SPRI kit (Beckman Coulter, USA), and eluted in RNasefree water for SERS measurements or amplicon size validation by agarose gel electrophoresis.
SERS Measurements
1 µL of target amplicon was incubated with 60 µl of cationic AgNPs for 15 min prior to SERS measurements. SERS measurements were performed using a portable IM-52 Raman Microscope with a 70 mW, 785 nm laser for excitation. The SERS spectra were collected in solution at 1 s illumination to minimize signal variations, and in the range of 400-1800 cm -1 .
Each sample was represented with the average spectrum of 10 measurements in the whole sampled volume.
%SERS_MiPS Score Calculation
For each sample, T2:ERG and PCA3 SERS signals were normalized to KLK2 SERS signal, in order to correct for the number of prostate cells in a single sample. For example:
Normalized T2:ERG SERS signal = T2:ERG SERS signal / KLK2 SERS signal Based partially on the algorithm of the standard clinical MiPS test, 24 we calculated our %SERS_MiPS Score through association with pathological data from the training cohort: 
Chemometric Analysis
The raw SERS spectra were firstly baseline-corrected to remove background noise using the Vancouver Raman Algorithm (a five-order polynomial fitting algorithm). 30 As each SERS 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 spectrum in the range of 400-1800 cm -1 possessed 1401 variables, PCA was then applied to capture main variables that were represented by principal components (PCs). Spectrum i is in the form as:
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